• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results

    Simply Wall St·01/08/2026 11:29:06
    Listen to the news

    Jazz Pharmaceuticals (JAZZ) is back in focus after reporting Phase 3 HERIZON-GEA-01 results for its HER2-targeted drug Ziihera in gastroesophageal cancer, highlighting meaningful gains in progression-free and overall survival versus current treatment.

    See our latest analysis for Jazz Pharmaceuticals.

    The Ziihera update lands at a time when Jazz Pharmaceuticals’ share price has been relatively firm, with a 90 day share price return of 22.6% and a 1 year total shareholder return of 40.87%. This suggests momentum has been building around its pipeline and recent trial headlines, despite a slightly negative year to date share price return.

    If this kind of late stage data is on your radar, it might also be worth scanning other healthcare stocks that could be setting up for their own catalysts.

    With Ziihera’s Phase 3 data in hand, Jazz Pharmaceuticals now pairs a 40.9% 1 year total return with an intrinsic value estimate suggesting a wide discount. The key question is whether this represents a genuine opportunity or if the market is already pricing in what comes next.

    Most Popular Narrative: 20.5% Undervalued

    Against Jazz Pharmaceuticals’ last close of US$169.37, the most followed fair value estimate of US$213.00 points to a sizable valuation gap built on oncology expectations.

    Bullish analysts view Ziihera as a potential new standard of care in first line HER2 positive GEA, supporting peak sales expectations above $2B and underpinning higher long term revenue growth assumptions.

    The breadth of HER2 positive tumor types where current biologics are entrenched leads some to frame Ziihera as a pipeline in a drug, which they see as justifying richer oncology multiples and a move toward the upper end of historical valuation ranges.

    Read the complete narrative.

    Curious how a company that is currently loss making gets to that higher value? The narrative leans on stronger margins, higher revenue, and a future earnings multiple more typical of established large caps. Want to see how those pieces fit together into that single fair value number?

    Result: Fair Value of $213 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this upbeat narrative can be knocked off course if oxybate revenues are hit by upcoming generic competition or if Ziihera’s commercial uptake and pricing fall short.

    Find out about the key risks to this Jazz Pharmaceuticals narrative.

    Build Your Own Jazz Pharmaceuticals Narrative

    If you are not fully on board with this setup or simply prefer to weigh the numbers yourself, you can build your own view in minutes, starting with Do it your way.

    A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    If you stop here, you could miss other opportunities that fit your style. Use the screener to quickly surface ideas that match what you care about most.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.